Why Is COVID-19 More Severe in Patients With Diabetes? The Role of Angiotensin-Converting Enzyme 2, Endothelial Dysfunction and the Immunoinflammatory System

Jacob Roberts1, Antonia L. Pritchard1, Andrew T. Treweeke1, Adriano G. Rossi2, Nicole Brace1, Paul A. Cahill3, Sandra MacRury1, Jun Wei1, Ian L. Megson1
1Institute for Health Research and Innovation, University of the Highlands and Islands, Inverness, United Kingdom
2Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom
3School of Biotechnology, Dublin City University, Dublin, Ireland

Tóm tắt

Meta-analyses have indicated that individuals with type 1 or type 2 diabetes are at increased risk of suffering a severe form of COVID-19 and have a higher mortality rate than the non-diabetic population. Patients with diabetes have chronic, low-level systemic inflammation, which results in global cellular dysfunction underlying the wide variety of symptoms associated with the disease, including an increased risk of respiratory infection. While the increased severity of COVID-19 amongst patients with diabetes is not yet fully understood, the common features associated with both diseases are dysregulated immune and inflammatory responses. An additional key player in COVID-19 is the enzyme, angiotensin-converting enzyme 2 (ACE2), which is essential for adhesion and uptake of virus into cells prior to replication. Changes to the expression of ACE2 in diabetes have been documented, but they vary across different organs and the importance of such changes on COVID-19 severity are still under investigation. This review will examine and summarise existing data on how immune and inflammatory processes interplay with the pathogenesis of COVID-19, with a particular focus on the impacts that diabetes, endothelial dysfunction and the expression dynamics of ACE2 have on the disease severity.

Từ khóa


Tài liệu tham khảo

Yelin, 2020, Long-term consequences of COVID-19: research needs, Lancet Infect Dis, 20, 1115, 10.1016/S1473-3099(20)30701-5

Zheng, 2020, Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis, J Infect, 81, e16, 10.1016/j.jinf.2020.04.021

Gold, 2020, COVID-19 and comorbidities: a systematic review and meta-analysis, Postgrad Med, 132, 1, 10.1080/00325481.2020.1786964

Mantovani, 2020, Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a meta-analysis of observational studies, Nutr Metab Cardiovasc Dis, 30, 1236, 10.1016/j.numecd.2020.05.014

Yang, 2020, Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis, Int J Infect Dis., 94, 91, 10.1016/j.ijid.2020.03.017

Yang, 2020, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, 8, 475, 10.1016/S2213-2600(20)30079-5

Zuin, 2020, Arterial hypertension and risk of death in patients with COVID-19 infection: systematic review and meta-analysis, J Infect, 81, e84, 10.1016/j.jinf.2020.03.059

Lee, 2020, Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study, Lancet Psychiatry, 7, P1025, 10.1016/S2215-0366(20)30421-1

Dyett, 2020, Possible link between obesity and severe COVID-19, Med J Aust, 213, 380, 10.5694/mja2.50793

Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, 1054, 10.1016/S0140-6736(20)30566-3

Zhu, 2020, Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing Type 2 diabetes, Cell Metab, 31, 1068, 10.1016/j.cmet.2020.04.021

Wu, 2020, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med, 180, 934, 10.1001/jamainternmed.2020.0994

Chen, 2020, Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study, BMJ, 368, m1091, 10.1136/bmj.m1091

Tu, 2020, Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan, Intensive Care Med, 46, 1117, 10.1007/s00134-020-06023-4

Chen, 2020, Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: a single-centered, retrospective study, J Gerontol A Biol Sci Med Sci, 75, 1788, 10.1093/gerona/glaa089

Yao, 2020, A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients, Pol Arch Intern Med, 130, 390, 10.20452/pamw.15312

Zhang, 2020, The clinical data from 19 critically ill patients with coronavirus disease 2019: a single-centered, retrospective, observational study, Z Gesundh Wiss, 10.21203/rs.3.rs-20800/v1

Wang, 2020, 15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispective observational cohort study, Intensive Care Med, 46, 1472, 10.1007/s00134-020-06047-w

Li, 2020, Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) Infection in Wuhan, China, JAMA Cardiol, 5, 825, 10.1001/jamacardio.2020.1624

Inciardi, 2020, Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy, Eur Heart J, 41, 1821, 10.1093/eurheartj/ehaa388

Du, 2020, Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study, Eur Respir J, 55, 2000524, 10.1183/13993003.00524-2020

Guan, 2020, Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis, Eur Respir J, 55, 2001227, 10.1183/13993003.01227-2020

2020, The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China, Zhonghua Liu Xing Bing Xue Za Zhi, 41, 145, 10.3760/cma.j.issn.0254-6450.2020.02.003

Guan, 2020, Clinical characteristics of Coronavirus Disease 2019 in China, N Engl J Med, 382, 1708, 10.1056/NEJMoa2002032

Deng, 2020, Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study, Chin Med J, 133, 1261, 10.1097/CM9.0000000000000824

Wang, 2020, Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up, J Infect, 80, 639, 10.1016/j.jinf.2020.03.019

de Almeida-Pititto, 2020, Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis, Diabetol Metab Syndr, 12, 75, 10.1186/s13098-020-00586-4

Ruan, 2020, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med, 46, 846, 10.1007/s00134-020-05991-x

Wang, 2020, Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19, Am J Respir Crit Care Med, 201, 1430, 10.1164/rccm.202003-0736LE

Liu, 2020, Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19, J Infect, 81, e6, 10.1016/j.jinf.2020.04.002

Cao, 2020, Clinical features and short-term outcomes of 102 patients with Coronavirus Disease 2019 in Wuhan, China, Clin Infect Dis, 71, 748, 10.1093/cid/ciaa243

Kumar, 2020, Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis, Diabetes Metab Syndr, 14, 535, 10.1016/j.dsx.2020.04.044

Akbari, 2020, Early epidemiological analysis of COVID-19: first report from South of Iran, Res Square, 10.21203/rs.3.rs-19915/v1

Bai, 2020, Clinical and laboratory factors predicting the prognosis of patients with COVID-19: an analysis of 127 patients in Wuhan, China, Lancet Respir Med, 10.2139/ssrn.3546118

Lu, 2020, Clinical characteristics and risk factors for fatal outcome in patients with 2019-Coronavirus Infected Disease (COVID-19) in Wuhan, Lancet, 10.2139/ssrn.3546069

Fu, 2020, Influence factors of death risk among COVID-19 patients in Wuhan, China: a hospital-based case-cohort study, medRxiv, 10.1101/2020.03.13.20035329

Li, 2020, Predictors of fatality including radiographic findings in adults with COVID-19, Respir Res., 21, 146, 10.1186/s12931-020-01411-2

Luo, 2020, Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China, medRxiv, 10.1101/2020.03.19.20033175

Yuan, 2020, Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China, PLoS ONE, 15, e0230548, 10.1371/journal.pone.0230548

Huang, 2020, Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression, Diabetes Metab Syndr, 14, 395, 10.1016/j.dsx.2020.04.018

Wang, 2020, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, 323, 1061, 10.1001/jama.2020.1585

Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5

Chen, 2020, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, 395, 507, 10.1016/S0140-6736(20)30211-7

Chen, 2020, Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia, Zhonghua Jie He He Hu Xi Za Zhi, 43, E005, 10.3760/cma.j.issn.1001-0939.2020.0005

Fu, 2020, Analysis on the clinical characteristics of 36 cases of novel coronavirus pneumonia in Kunming, medRxiv, 10.1101/2020.02.28.20029173

Guo, 2020, Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19), JAMA Cardiol, 5, 811, 10.1001/jamacardio.2020.1017

Liu, 2020, Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province, Chin Med J, 133, 1025, 10.1097/CM9.0000000000000744

Liu, 2020, The epidemiological and clinical characteristics of 2019 novel coronalvirus infection in Changsha, China, Lancet Infect Dis, 10.2139/ssrn.3537093

Peng, 2020, Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV, Zhonghua Xin Xue Guan Bing Za Zhi, 48, 450, 10.3760/cma.j.cn112148-20200220-00105

Shi, 2020, Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study, Lancet Infect Dis, 20, 425, 10.1016/S1473-3099(20)30086-4

Shi, 2020, Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China, JAMA Cardiol, 5, 802, 10.1001/jamacardio.2020.0950

Tang, 2020, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost, 18, 844, 10.1111/jth.14768

Wang, 2020, Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China, Clin Infect Dis, 71, 769, 10.1093/cid/ciaa272

Xu, 2020, Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series, BMJ, 368, m606, 10.1136/bmj.m606

Miller, 2020, Diabetes mellitus increases the risk of hospital mortality in patients with Covid-19: systematic review with meta-analysis, Medicine, 99, e22439, 10.1097/MD.0000000000022439

Du, 2020, Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study, Am J Respir Crit Care Med, 201, 1372, 10.1164/rccm.202003-0543OC

Li, 2020, Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China, Int J Infect Dis, 94, 128, 10.1016/j.ijid.2020.03.053

Richardson, 2020, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area, JAMA, 323, 2052, 10.1001/jama.2020.6775

Hussain, 2020, Burden of diabetes mellitus and its impact on COVID-19 patients: a meta-analysis of real-world evidence, Diabetes Metab Syndr, 14, 1595, 10.1016/j.dsx.2020.08.014

Gu, 2020, History of coronary heart disease increases the mortality rate of COVID-19 patients: a nested case-control study, BMJ Open., 10, e038976, 10.1136/bmjopen-2020-038976

2020, Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study, Lancet, 396, 27, 10.1016/S0140-6736(20)31182-X

Chen, 2020, Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication, Diabetes Care, 43, 1399, 10.2337/dc20-0660

Zhang, 2020, Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: a single center retrospective cohort study, medRxiv, 10.1101/2020.03.21.20040121

Ssentongo, 2020, Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: a systematic review and meta-analysis, PLoS ONE, 15, e0238215, 10.1371/journal.pone.0238215

Holman, 2020, Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study, Lancet Diabetes Endocrinol, 8, 823, 10.1016/S2213-8587(20)30271-0

Barron, 2020, Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study, Lancet Diabetes Endocrinol, 8, 813, 10.1016/S2213-8587(20)30272-2

Beagley, 2014, Global estimates of undiagnosed diabetes in adults, Diabetes Res Clin Pract, 103, 150, 10.1016/j.diabres.2013.11.001

Unsworth, 2020, New-onset type 1 diabetes in children during COVID-19: multicenter regional findings in the U.K., Diabetes Care, 43, e170, 10.2337/dc20-1551

Pung, 2020, Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures, Lancet, 395, 1039, 10.1016/S0140-6736(20)30528-6

Lauer, 2020, The incubation period of Coronavirus Disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application, Ann Intern Med, 172, 577, 10.7326/M20-0504

Li, 2020, Early Transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N Engl J Med, 382, 1199, 10.1056/NEJMoa2001316

Song, 2020, Immunological and inflammatory profiles in mild and severe cases of COVID-19, Nat Commun, 11, 3410, 10.1038/s41467-020-17240-2

Chen, 2020, Clinical and immunological features of severe and moderate coronavirus disease 2019, J Clin Invest, 130, 2620, 10.1172/JCI137244

Keeley, 2020, Symptom burden and clinical profile of COVID-19 deaths: a rapid systematic review and evidence summary, BMJ Support Palliat Care, 10, 381, 10.1136/bmjspcare-2020-002368

Zhou, 2020, Imaging features and evolution on CT in 100 COVID-19 pneumonia patients in Wuhan, China, Eur Radiol, 30, 5446, 10.1007/s00330-020-06879-6

Fei, 2020, Coagulation Dysfunction, Arch Pathol Lab Med, 144, 1223, 10.5858/arpa.2020-0324-SA

Connors, 2020, COVID-19 and its implications for thrombosis and anticoagulation, Blood, 135, 2033, 10.1182/blood.2020006000

Tavakolpour, 2020, Lymphopenia during the COVID-19 infection: what it shows and what can be learned, Immunol Lett, 225, 31, 10.1016/j.imlet.2020.06.013

Wang, 2020, Temporal changes of CT findings in 90 patients with COVID-19 Pneumonia: a Longitudinal Study, Radiology, 296, E55, 10.1148/radiol.2020200843

Radermecker, 2020, Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19, J Exp Med, 217, e20201012, 10.1084/jem.20201012

Carsana, 2020, Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study, Lancet Infect Dis, 20, 1135, 10.1016/S1473-3099(20)30434-5

Liu, 2020, Viral dynamics in mild and severe cases of COVID-19, Lancet Infect Dis, 20, 656, 10.1016/S1473-3099(20)30232-2

Sungnak, 2020, SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes, Nat Med, 26, 681, 10.1038/s41591-020-0868-6

Al-Sarraj, 2020, The spectrum of neuropathology in COVID-19, Neuropathol Appl Neurobiol, 10.1111/nan.12667

Vasquez-Bonilla, 2020, A review of the main histopathological findings in coronavirus disease 2019, Hum Pathol, 105, 74, 10.1016/j.humpath.2020.07.023

Wu, 2020, Substantial underestimation of SARS-CoV-2 infection in the United States, Nat Commun, 11, 4507, 10.1038/s41467-020-18272-4

Sette, 2020, Pre-existing immunity to SARS-CoV-2: the knowns and unknowns, Nat Rev Immunol, 20, 457, 10.1038/s41577-020-0389-z

Le, 2020, SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls, Nature, 584, 457, 10.1038/s41586-020-2550-z

Lee, 2020, Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a Community Treatment Center in the Republic of Korea, JAMA Intern Med, 180, 1447, 10.1001/jamainternmed.2020.3862

Eckerle, 2020, SARS-CoV-2 seroprevalence in COVID-19 hotspots, Lancet, 396, 514, 10.1016/S0140-6736(20)31482-3

Alanagreh, 2020, The Human Coronavirus Disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms, Pathogens, 9, 331, 10.3390/pathogens9050331

Fehr, 2015, Coronaviruses: an overview of their replication and pathogenesis, Methods Mol Biol, 1282, 1, 10.1007/978-1-4939-2438-7

Yao, 2020, Molecular Architecture of the SARS-CoV-2 Virus, Cell, 183, 730, 10.1101/2020.07.08.192104

Skowronski, 2005, Severe acute respiratory syndrome (SARS): a year in review, Annu Rev Med, 56, 357, 10.1146/annurev.med.56.091103.134135

Zumla, 2015, Middle East respiratory syndrome, Lancet, 386, 995, 10.1016/S0140-6736(15)60454-8

Khailany, 2020, Genomic characterization of a novel SARS-CoV-2, Gene Rep, 19, 100682, 10.1016/j.genrep.2020.100682

Lan, 2020, Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor, Nature, 581, 215, 10.1038/s41586-020-2180-5

Sehnal, 2018, Mol*: Towards a common library and tools for web molecular graphics, MolVA/EuroVis Proceedings

Kuba, 2010, Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters, Pharmacol Ther, 128, 119, 10.1016/j.pharmthera.2010.06.003

Zhang, 2007, Collectrin, a homologue of ACE2, its transcriptional control and functional perspectives, Biochem Biophys Res Commun, 363, 1, 10.1016/j.bbrc.2007.08.136

Zhou, 2020, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579, 270, 10.1038/s41586-020-2012-7

Hoffmann, 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052

Walls, 2020, Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell, 181, 281, 10.1016/j.cell.2020.02.058

Xia, 2020, Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein, Cell Mol Immunol, 17, 765, 10.1038/s41423-020-0374-2

Liu, 2004, Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors, Lancet, 363, 938, 10.1016/S0140-6736(04)15788-7

Xu, 2004, Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus, Biochemistry, 43, 14064, 10.1021/bi049101q

Gui, 2017, Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding, Cell Res, 27, 119, 10.1038/cr.2016.152

Yuan, 2017, Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains, Nat Commun, 8, 15092, 10.1038/ncomms15092

Shang, 2020, Cell entry mechanisms of SARS-CoV-2, Proc Natl Acad Sci USA, 117, 11727, 10.1073/pnas.2003138117

McKinney, 2014, Angiotensin-(1–7) and angiotensin-(1–9): function in cardiac and vascular remodelling, Clin Sci, 126, 815, 10.1042/CS20130436

Carey, 2003, Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation, Endocr Rev, 24, 261, 10.1210/er.2003-0001

Hayashi, 2010, The counterregulating role of ACE2 and ACE2-mediated angiotensin 1–7 signaling against angiotensin II stimulation in vascular cells, Hypertens Res, 33, 1182, 10.1038/hr.2010.147

Benigni, 2010, Angiotensin II revisited: new roles in inflammation, immunology and aging, EMBO Mol Med, 2, 247, 10.1002/emmm.201000080

Garvin, 2020, A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm, Elife, 9, e59177, 10.7554/eLife.59177

Turner, 2004, ACE2: from vasopeptidase to SARS virus receptor, Trends Pharmacol Sci, 25, 291, 10.1016/j.tips.2004.04.001

Hamming, 2004, Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J Pathol, 203, 631, 10.1002/path.1570

Zou, 2020, Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection, Front Med, 14, 185, 10.1007/s11684-020-0754-0

Guy, 2005, Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis, FEBS J, 272, 3512, 10.1111/j.1742-4658.2005.04756.x

Lambert, 2005, Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2), J Biol Chem, 280, 30113, 10.1074/jbc.M505111200

Heurich, 2014, TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein, J Virol, 88, 1293, 10.1128/JVI.02202-13

Epelman, 2008, Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system, J Am Coll Cardiol, 52, 750, 10.1016/j.jacc.2008.02.088

Patel, 2014, Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS, J Mol Cell Cardiol, 66, 167, 10.1016/j.yjmcc.2013.11.017

Tipnis, 2000, A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase, J Biol Chem, 275, 33238, 10.1074/jbc.M002615200

Zoufaly, 2020, Human recombinant soluble ACE2 in severe COVID-19, Lancet Respir Med, 8, 1154, 10.1016/S2213-2600(20)30418-5

Batlle, 2020, Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?, Clin Sci, 134, 543, 10.1042/CS20200163

Blanco-Melo, 2020, Imbalanced host response to SARS-CoV-2 drives development of COVID-19, Cell, 181, 1036, 10.1016/j.cell.2020.04.026

Brubaker, 2015, Innate immune pattern recognition: a cell biological perspective, Annu Rev Immunol, 33, 257, 10.1146/annurev-immunol-032414-112240

Heil, 2004, Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8, Science, 303, 1526, 10.1126/science.1093620

Zhang, 2018, Structural analyses of toll-like receptor 7 reveal detailed RNA sequence specificity and recognition mechanism of agonistic ligands, Cell Rep, 25, 3371, 10.1016/j.celrep.2018.11.081

Tanji, 2015, Toll-like receptor 8 senses degradation products of single-stranded RNA, Nat Struct Mol Biol, 22, 109, 10.1038/nsmb.2943

Honda, 2006, Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors, Immunity, 25, 349, 10.1016/j.immuni.2006.08.009

Tenoever, 2007, Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity, Science, 315, 1274, 10.1126/science.1136567

Ran, 2014, MITA/STING: a central and multifaceted mediator in innate immune response, Cytokine Growth Factor Rev, 25, 631, 10.1016/j.cytogfr.2014.05.003

Barber, 2011, Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses, Curr Opin Immunol, 23, 10, 10.1016/j.coi.2010.12.015

Maringer, 2014, Message in a bottle: lessons learned from antagonism of STING signalling during RNA virus infection, Cytokine Growth Factor Rev, 25, 669, 10.1016/j.cytogfr.2014.08.004

Wu, 2019, Inflammasome activation triggers blood clotting and host death through pyroptosis, Immunity, 50, 1401, 10.1016/j.immuni.2019.04.003

Yap, 2020, Inflammasomes and pyroptosis as therapeutic targets for COVID-19, J Immunol, 205, 307, 10.4049/jimmunol.2000513

Berthelot, 2020, Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway?, Emerg Microbes Infect, 9, 1514, 10.1080/22221751.2020.1785336

Zhang, 2020, STING is an essential regulator of heart inflammation and fibrosis in mice with pathological cardiac hypertrophy via endoplasmic reticulum (ER) stress, Biomedicine & Pharmacotherapy, 125, 110022, 10.1016/j.biopha.2020.110022

Borden, 2007, Interferons at age 50: past, current and future impact on biomedicine, Nat Rev Drug Discovery, 6, 975, 10.1038/nrd2422

Grifoni, 2020, Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals, Cell, 181, 1489, 10.1016/j.cell.2020.05.015

Sekine, 2020, Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19, Cell, 183, 158, 10.1101/2020.06.29.174888

Wang, 2020, Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients, Clin Infect Dis, 10.1101/2020.04.15.20065623

Ng, 2020, Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans, Science., 370, 1339, 10.1126/science.abe1107

Wu, 2020, Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications, medRxiv, 10.2139/ssrn.3566211

Muecksch, 2020, Longitudinal analysis of serology and neutralizing antibody levels in COVID19 convalescents, jiaa659, 10.1093/infdis/jiaa659

Chen, 2020, T cell responses in patients with COVID-19, Nat Rev Immunol, 20, 529, 10.1038/s41577-020-0402-6

Long, 2020, Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections, Nat Med, 26, 1200, 10.1038/s41591-020-0965-6

Lee, 2020, Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19, Sci Immunol, 5, abd1554, 10.1126/sciimmunol.abd1554

Acharya, 2020, Dysregulation of type I interferon responses in COVID-19, Nat Rev Immunol, 20, 397, 10.1038/s41577-020-0346-x

Hadjadj, 2020, Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients, Science, 369, 718, 10.1126/science.abc6027

Wang, 2020, Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts, J Leukoc Biol, 108, 17, 10.1002/JLB.3COVR0520-272R

Yang, 2020, Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19, J Allergy Clin Immunol, 146, 119, 10.1016/j.jaci.2020.04.027

Mann, 2020, Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19, Sci Immunol, 5, abd6197, 10.1126/sciimmunol.abd6197

Qin, 2020, Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China, Clin Infect Dis, 71, 762, 10.1093/cid/ciaa248

Bryce, 2020, Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience, medRxiv, 10.1101/2020.05.18.20099960

Zhang, 2020, COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes, J Leukoc Biol, 109, 13, 10.1002/JLB.4HI0720-470R

Muir, 2016, Innate lymphoid cells are the predominant source of il-17a during the early pathogenesis of acute respiratory distress syndrome, Am J Respir Crit Care Med, 193, 407, 10.1164/rccm.201410-1782OC

Tang, 2020, Cytokine Storm in COVID-19: the current evidence and treatment strategies, Front Immunol, 11, 1708, 10.3389/fimmu.2020.01708

Ragab, 2020, The COVID-19 cytokine storm; what we know so far, Front Immunol, 11, 1446, 10.3389/fimmu.2020.01446

Gao, 2020, Cytokine storm syndrome in coronavirus disease 2019: a narrative review, J Intern Med, 10.1111/joim.13144

Leisman, 2020, Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes, Lancet Respir Med, 8, 1233, 10.1016/S2213-2600(20)30404-5

Mazzoni, 2020, Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent, J Clin Invest, 130, 4694, 10.1172/JCI138554

Diao, 2020, Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19), Front Immunol, 11, 827, 10.3389/fimmu.2020.00827

Zheng, 2020, Functional exhaustion of antiviral lymphocytes in COVID-19 patients, Cell Mol Immunol, 17, 533, 10.1038/s41423-020-0402-2

2020, Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison, Lancet Infect Dis, 20, 1390, 10.1016/S1473-3099(20)30634-4

Whitman, 2020, Evaluation of SARS-CoV-2 serology assays reveals a range of test performance, Nat Biotechnol, 38, 1174, 10.1038/s41587-020-0659-0

Faustini, 2020, Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and saliva enhances detection of infection, medRxiv, 10.1101/2020.06.16.20133025

Yu, 2020, Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients, Eur Respir J, 56, 2020, 10.1183/13993003.01526-2020

Ma, 2020, Serum IgA, IgM, and IgG responses in COVID-19, Cell Mol Immunol, 17, 773, 10.1038/s41423-020-0474-z

Hasan, 2020, Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies, Clin Infect Dis., ciaa1496, 10.1093/cid/ciaa1496

Varadhachary, 2020, Salivary anti-SARS-CoV-2 IgA as an :accessible biomarker of mucosal immunity against COVID-19, medRxiv, 10.1101/2020.08.07.20170258

Zhang, 2020, Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19, Front Mol Biosci, 7, 157, 10.3389/fmolb.2020.00157

Alexandraki, 2008, Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation, J Clin Immunol, 28, 314, 10.1007/s10875-007-9164-1

Davidson, 1984, Defective phagocytosis in insulin controlled diabetics: evidence for a reaction between glucose and opsonising proteins, J Clin Pathol, 37, 783, 10.1136/jcp.37.7.783

Delamaire, 1997, Impaired leucocyte functions in diabetic patients, Diabet Med, 14, 29, 10.1002/(SICI)1096-9136(199701)14:1<29::AID-DIA300>3.0.CO;2-V

Huang, 2019, Distinct neutrophil counts and functions in newly diagnosed type 1 diabetes, latent autoimmune diabetes in adults, and type 2 diabetes, Diabetes Metab Res Rev, 35, e3064, 10.1002/dmrr.3064

Lecube, 2011, Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement, PLoS ONE, 6, e23366, 10.1371/journal.pone.0023366

Marhoffer, 1992, Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes, Diabetes Care, 15, 256, 10.2337/diacare.15.2.256

Hull, 2017, Regulatory T cell dysfunction in type 1 diabetes: what's broken and how can we fix it?, Diabetologia, 60, 1839, 10.1007/s00125-017-4377-1

Blandino-Rosano, 2008, Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide−1, J Mol Endocrinol, 41, 35, 10.1677/JME-07-0154

Okubo, 2016, Treg activation defect in type 1 diabetes: correction with TNFR2 agonism, Clin Transl Immunol, 5, e56, 10.1038/cti.2015.43

Ip, 2016, Th17 cytokines differentiate obesity from obesity-associated type 2 diabetes and promote TNFalpha production, Obesity, 24, 102, 10.1002/oby.21243

Shen, 2019, Metabolic regulation of TH17 cells, Mol Immunol, 109, 81, 10.1016/j.molimm.2019.03.005

Nicholas, 2019, Fatty acid metabolites combine with reduced beta oxidation to activate Th17 inflammation in human type 2 diabetes, Cell Metab, 30, 447, 10.1016/j.cmet.2019.07.004

Carey, 2018, Risk of infection in Type 1 and Type 2 diabetes compared with the general population: a matched cohort study, Diabetes Care, 41, 513, 10.2337/dc17-2131

Critchley, 2018, Glycemic control and risk of infections among people with type 1 or Type 2 diabetes in a large primary care Cohort Study, Diabetes Care, 41, 2127, 10.2337/dc18-0287

Wang, 2020, Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study, Diabetologia, 63, 2102, 10.1007/s00125-020-05209-1

Liu, 2020, Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury, Sci China Life Sci, 63, 364, 10.1007/s11427-020-1643-8

Henry, 2020, Circulating plasma levels of angiotensin II and aldosterone in patients with coronavirus disease 2019 (COVID-19): a preliminary report, Prog Cardiovasc Dis, 63, 702, 10.1016/j.pcad.2020.07.006

Jarcho, 2020, Inhibitors of the renin-angiotensin-aldosterone system and Covid-19, N Engl J Med, 382, 2462, 10.1056/NEJMe2012924

Tralhao, 2020, Potential benefit of angiotensin II in COVID-19 patients: beyond reasonable doubt?, Crit Care, 24, 324, 10.1186/s13054-020-03027-w

Flacco, 2020, Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis, Heart, 106, 1519, 10.1136/heartjnl-2020-317336

Vaduganathan, 2020, Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19, N Engl J Med, 382, 1653, 10.1056/NEJMsr2005760

Aronson, 2020, Drugs and the renin-angiotensin system in covid-19, BMJ, 369, m1313, 10.1136/bmj.m1313

Hippisley-Cox, 2020, Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people, Heart, 106, 1503, 10.1136/heartjnl-2020-317393

Braude, 2020, The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19, IJC Heart Vasculature, 31, 100660, 10.1016/j.ijcha.2020.100660

Mehra, 2020, Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19, New England J Med, 382, e102, 10.1056/NEJMoa2007621

Koka, 2008, Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway, Am J Pathol, 172, 1174, 10.2353/ajpath.2008.070762

Soler, 2007, ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice, Kidney Int, 72, 614, 10.1038/sj.ki.5002373

Chen, 2020, Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation, Aging Cell, 19, e13168, 10.1111/acel.13168

Anderson, 1993, Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations, Am J Physiol, 265, F477, 10.1152/ajprenal.1993.265.4.F477

Tikellis, 2003, Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy, Hypertension, 41, 392, 10.1161/01.HYP.0000060689.38912.CB

Rao, 2020, Exploring Diseases/traits and blood proteins causally related to expression of ACE2, the Putative Receptor of SARS-CoV-2: a mendelian randomization analysis highlights tentative relevance of diabetes-related traits, Diabetes Care, 43, 1416, 10.2337/dc20-0643

Roca-Ho, 2017, Characterization of ACE and ACE2 expression within different organs of the NOD mouse, Int J Mol Sci, 18, 563, 10.3390/ijms18030563

Fang, 2020, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?, Lancet Respir Med, 8, e21, 10.1016/S2213-2600(20)30116-8

Muller, 2005, Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus, Clin Infect Dis, 41, 281, 10.1086/431587

Kulcsar, 2019, Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection, JCI Insight, 4, e131774, 10.1172/jci.insight.131774

Hulme, 2017, Influenza virus and glycemic variability in diabetes: a killer combination?, Front Microbiol, 8, 861, 10.3389/fmicb.2017.00861

Carroll, 2010, Adaptive immunity to rhinoviruses: sex and age matter, Respir Res, 11, 184, 10.1186/1465-9921-11-184

Giefing-Kroll, 2015, How sex and age affect immune responses, susceptibility to infections, and response to vaccination, Aging Cell, 14, 309, 10.1111/acel.12326

Klein, 2012, Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases, Bioessays, 34, 1050, 10.1002/bies.201200099

Oh, 2019, Aging and the Immune System: the Impact of Immunosenescence on viral infection, immunity and vaccine immunogenicity, Immune Netw, 19, e37, 10.4110/in.2019.19.e37

Kautzky-Willer, 2016, Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus, Endocr Rev, 37, 278, 10.1210/er.2015-1137

Apicella, 2020, COVID-19 in people with diabetes: understanding the reasons for worse outcomes, Lancet Diabetes Endocrinol, 8, 782, 10.1016/S2213-8587(20)30238-2

Deng, 2016, Altered peripheral B-lymphocyte subsets in type 1 diabetes and latent autoimmune diabetes in adults, Diabetes Care, 39, 434, 10.2337/dc15-1765

Mira, 2017, Persistent inflammation, immunosuppression and catabolism syndrome, Crit Care Clin, 33, 245, 10.1016/j.ccc.2016.12.001

Hawkins, 2018, Chronic critical illness and the persistent inflammation, immunosuppression, and catabolism syndrome, Front Immunol, 9, 1511, 10.3389/fimmu.2018.01511

Salminen, 2021, Increased immunosuppression impairs tissue homeostasis with aging and age-related diseases, J Mol Med, 99, 1, 10.1007/s00109-020-01988-7

Rydyznski, 2020, Antigen-specific adaptive immunity to SARS-CoV-2 in Acute COVID-19 and associations with age and disease severity, Cell, 183, 996, 10.1016/j.cell.2020.09.038

Daoust, 2020, Elderly people and responses to COVID-19 in 27 Countries, PLoS ONE, 15, e0235590, 10.1371/journal.pone.0235590

Cicco, 2020, Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment, Mediators Inflamm, 2020, 7527953, 10.1155/2020/7527953

Land, 2020, Role of damage-associated molecular patterns in light of modern environmental research: a tautological approach, Int J Environ Res, 14, 583, 10.1007/s41742-020-00276-z

AlGhatrif, 2020, The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science, JAMA Cardiol, 5, 747, 10.1001/jamacardio.2020.1329

Tomar, 2020, Neutrophils and neutrophil extracellular traps drive necroinflammation in COVID-19, Cells, 9, 1383, 10.3390/cells9061383

Webb, 2020, Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study, Lancet Rheumatol, 2, e754, 10.1016/S2665-9913(20)30343-X

Williamson, 2020, OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients, Nature., 584, 430, 10.1038/s41586-020-2521-4

Thierry, 2020, Neutrophil extracellular traps and by-products play a key role in COVID-19: pathogenesis, risk factors, and therapy, J Clin Med, 9, 2942, 10.3390/jcm9092942

Kalyanaraman, 2020, Do free radical NETwork and oxidative stress disparities in African Americans enhance their vulnerability to SARS-CoV-2 infection and COVID-19 severity?, Redox Biol, 37, 101721, 10.1016/j.redox.2020.101721

Wang, 2020, Neutrophil-to-lymphocyte ratio at admission is an independent risk factors for the severity and mortality in patients with coronavirus disease 2019, J Infect, 10.1016/j.jinf.2020.09.022

Veras, 2020, SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology, J Exp Med, 217, e20201129, 10.1084/jem.20201129

de Vries, 2020, Effects of diabetes mellitus on fibrin clot structure and mechanics in a model of acute Neutrophil Extracellular Traps (NETs) Formation, Int J Mol Sci, 21, 7107, 10.3390/ijms21197107

Jin, 2020, Neutrophil extracellular traps (NETs)-mediated killing of carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) are impaired in patients with diabetes mellitus, Virulence, 11, 1122, 10.1080/21505594.2020.1809325

Birra, 2020, COVID 19: a clue from innate immunity, Immunol Res, 68, 161, 10.1007/s12026-020-09137-5

Bandyopadhyay, 2020, COVID-19 pandemic: cardiovascular complications and future implications, Am J Cardiovasc Drugs, 20, 311, 10.1007/s40256-020-00420-2

Clerkin, 2020, COVID-19 and cardiovascular disease, Circulation, 141, 1648, 10.1161/CIRCULATIONAHA.120.046941

Seirafianpour, 2020, Cutaneous manifestations and considerations in COVID-19 pandemic: a systematic review, Dermatol Ther, 33, e13986, 10.1111/dth.13986

Ackermann, 2020, Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19, N Engl J Med, 383, 120, 10.1056/NEJMoa2015432

Varga, 2020, Endothelial cell infection and endotheliitis in COVID-19, Lancet, 395, 1417, 10.1016/S0140-6736(20)30937-5

Le Brocq, 2008, Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities, Antioxid Redox Signal, 10, 1631, 10.1089/ars.2007.2013

Shaw, 2014, Endothelial cell oxidative stress in diabetes: a key driver of cardiovascular complications?, Biochem Soc Trans, 42, 928, 10.1042/BST20140113

Gu, 2012, Association of intercellular adhesion molecule 1 (ICAM1) with diabetes and diabetic nephropathy, Front Endocrinol, 3, 179, 10.3389/fendo.2012.00179

Ribau, 1999, Endothelial adhesion molecule expression is enhanced in the aorta and internal mammary artery of diabetic patients, J Surg Res, 85, 225, 10.1006/jsre.1999.5682

McLeod, 1995, Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid, Am J Pathol, 147, 642

Lim, 2004, Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention, Circulation, 109, 2524, 10.1161/01.CIR.0000129773.70647.94

Sandoo, 2010, The endothelium and its role in regulating vascular tone, Open Cardiovasc Med J, 4, 302, 10.2174/1874192401004010302

Gimbrone, 2016, Endothelial cell dysfunction and the pathobiology of atherosclerosis, Circ Res, 118, 620, 10.1161/CIRCRESAHA.115.306301

Moncada, 1997, Nitric oxide in the vasculature: physiology and pathophysiology, Ann N Y Acad Sci, 811, 60, 10.1111/j.1749-6632.1997.tb51989.x

Radomski, 1987, The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide, Br J Pharmacol, 92, 639, 10.1111/j.1476-5381.1987.tb11367.x

Moncada, 2006, Adventures in vascular biology: a tale of two mediators, Philos Trans R Soc Lond B Biol Sci, 361, 735, 10.1098/rstb.2005.1775

Darimont, 1994, In situ microdialysis of prostaglandins in adipose tissue: stimulation of prostacyclin release by angiotensin II, Int J Obes Relat Metab Disord, 18, 783

Cheng, 2002, Role of prostacyclin in the cardiovascular response to thromboxane A2, Science, 296, 539, 10.1126/science.1068711

Zellers, 1994, Interaction among ET-1, endothelium-derived nitric oxide, and prostacyclin in pulmonary arteries and veins, Am J Physiol, 267, H139, 10.1152/ajpheart.1994.267.1.H139

Tousoulis, 2012, The role of nitric oxide on endothelial function, Curr Vasc Pharmacol, 10, 4, 10.2174/157016112798829760

Noris, 1995, Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions, Circ Res, 76, 536, 10.1161/01.RES.76.4.536

Arnet, 1996, Regulation of endothelial nitric-oxide synthase during hypoxia, J Biol Chem, 271, 15069, 10.1074/jbc.271.25.15069

Godo, 2017, Divergent roles of endothelial nitric oxide synthases system in maintaining cardiovascular homeostasis, Free Radic Biol Med, 109, 4, 10.1016/j.freeradbiomed.2016.12.019

Salvemini, 2006, Superoxide, peroxynitrite and oxidative/nitrative stress in inflammation, Biochem Soc Trans, 34, 965, 10.1042/BST0340965

Stockklauser-Farber, 2000, Influence of diabetes on cardiac nitric oxide synthase expression and activity, Biochim Biophys Acta, 1535, 10, 10.1016/S0925-4439(00)00078-8

Endemann, 2004, Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus, Curr Hypertens Rep, 6, 85, 10.1007/s11906-004-0081-x

Treweeke, 2017, Preliminary study of hypoxia-related cardiovascular mediator-markers in patients with end-stage renal disease with and without diabetes and the effects of haemodialysis, PLoS ONE, 12, e0178171, 10.1371/journal.pone.0178171

Zafar, 2018, Association between the expression of vascular endothelial growth factors and metabolic syndrome or its components: a systematic review and meta-analysis, Diabetol Metab Syndr, 10, 62, 10.1186/s13098-018-0363-0

Wright, 1989, Generation of nitric oxide by human neutrophils, Biochem Biophys Res Commun, 160, 813, 10.1016/0006-291X(89)92506-0

Lambden, 2019, Bench to bedside review: therapeutic modulation of nitric oxide in sepsis-an update, Intensive Care Med Exp, 7, 64, 10.1186/s40635-019-0274-x

Alvarez, 2020, Home Nitric Oxide Therapy for COVID-19, Am J Respir Crit Care Med, 202, 16, 10.1164/rccm.202005-1906ED

Apte, 2019, VEGF in signaling and disease: beyond discovery and development, Cell, 176, 1248, 10.1016/j.cell.2019.01.021

Schulte, 2011, Stabilizing the VE-cadherin-catenin complex blocks leukocyte extravasation and vascular permeability, EMBO J, 30, 4157, 10.1038/emboj.2011.304

Forsythe, 1996, Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1, Mol Cell Biol, 16, 4604, 10.1128/MCB.16.9.4604

Burtenshaw, 2019, Reactive Oxygen Species (ROS), intimal thickening, and subclinical atherosclerotic disease, Front Cardiovasc Med, 6, 89, 10.3389/fcvm.2019.00089

Fiorello, 2020, The impact of glucose exposure on bioenergetics and function in a cultured endothelial cell model and the implications for cardiovascular health in diabetes, Sci Rep, 10, 19547, 10.1038/s41598-020-76505-4

Andre, 2004, P-selectin in haemostasis, Br J Haematol, 126, 298, 10.1111/j.1365-2141.2004.05032.x

Polgar, 2005, The P-selectin, tissue factor, coagulation triad, J Thromb Haemost, 3, 1590, 10.1111/j.1538-7836.2005.01373.x

Blann, 2003, The adhesion molecule P-selectin and cardiovascular disease, Eur Heart J, 24, 2166, 10.1016/j.ehj.2003.08.021

Tessaro, 2015, Lipid mediators are critical in resolving inflammation: a review of the emerging roles of eicosanoids in diabetes mellitus, BioMed Research International, 2015, 568408, 10.1155/2015/568408

Luo, 2011, Eicosanoids, β-cell function, and diabetes, Prostagl Other Lipid Mediators, 95, 1, 10.1016/j.prostaglandins.2011.06.001

Yan, 2006, Nucleocapsid protein of SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factor-kappa B and CCAAT/enhancer binding protein, Int J Biochem Cell Biol, 38, 1417, 10.1016/j.biocel.2006.02.003

Chopra, 2019, IRE1alpha-XBP1 signaling in leukocytes controls prostaglandin biosynthesis and pain, Science, 365, eaau6499, 10.1126/science.aau6499

Dennis, 2015, Eicosanoid storm in infection and inflammation, Nat Rev Immunol, 15, 511, 10.1038/nri3859

Vane, 1998, Mechanism of action of nonsteroidal anti-inflammatory drugs, Am J Med, 104, 2S, 10.1016/S0002-9343(97)00203-9

Ogawa, 2008, Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial, JAMA, 300, 2134, 10.1001/jama.2008.623

Belch, 2008, The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease, BMJ, 337, a1840, 10.1136/bmj.a1840

Pignone, 2010, Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation, Diabetes care, 33, 1395, 10.2337/dc10-0555

Group, 2018, Effects of aspirin for primary prevention in persons with diabetes mellitus, N Engl J Med, 379, 1529, 10.1056/NEJMoa1804988

Xing, 2019, Aspirin for primary prevention of cardiovascular disease in diabetes, J Diabetes Investig, 10, 899, 10.1111/jdi.13006

FitzGerald, 2001, The coxibs, selective inhibitors of cyclooxygenase-2, N Engl J Med, 345, 433, 10.1056/NEJM200108093450607

Howard, 2004, Nonsteroidal anti-inflammatory drugs and cardiovascular risk, J Am College Cardiol, 43, 519, 10.1016/j.jacc.2003.09.043

Belton, 2000, Cyclooxygenase-1 and−2-dependent prostacyclin formation in patients with atherosclerosis, Circulation, 102, 840, 10.1161/01.CIR.102.8.840

Catella-Lawson, 2001, Cyclooxygenase inhibitors and the antiplatelet effects of aspirin, N Engl J Med, 345, 1809, 10.1056/NEJMoa003199

Reichman, 1986, Effects of steroids and nonsteroid anti-inflammatory agents on vascular permeability in a rat glioma model, J Neurosurg, 65, 233, 10.3171/jns.1986.65.2.0233

Tarnawski, 2003, Inhibition of angiogenesis by NSAIDs: molecular mechanisms and clinical implications, J Mol Med, 81, 627, 10.1007/s00109-003-0479-y

Williams, 1973, Prostaglandins as potentiators of increased vascular permeability in inflammation, Nature, 246, 215, 10.1038/246215a0

Pai, 2001, PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways, Biochem Biophys Res Commun, 286, 923, 10.1006/bbrc.2001.5494

Mazzeo, 1998, Decreased IL-12 production and Th1 cell development by acetyl salicylic acid-mediated inhibition of NF-kappaB, Eur J Immunol, 28, 3205, 10.1002/(SICI)1521-4141(199810)28:10<3205::AID-IMMU3205>3.0.CO;2-8

Inaoka, 2006, Non-steroidal anti-inflammatory drugs selectively inhibit cytokine production by NK cells and gamma delta T cells, Exp Dermatol, 15, 981, 10.1111/j.1600-0625.2006.00505.x

Cianferoni, 2001, Selective inhibition of interleukin-4 gene expression in human T cells by aspirin, Blood, 97, 1742, 10.1182/blood.V97.6.1742

Torjesen, 2020, Covid-19: NICE advises against using NSAIDs for fever in patients with suspected cases, BMJ, 369, m1409, 10.1136/bmj.m1409

Qiao, 2015, Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats, Cardiology, 131, 97, 10.1159/000375362

Mancia, 2020, Renin-angiotensin-aldosterone system blockers and the risk of Covid-19, N Engl J Med, 382, 2431, 10.1056/NEJMoa2006923

Chen, 2020, Cyclooxgenase-2 is induced by SARS-CoV-2 infection but does not affect viral entry or replication, bioRxiv, 10.1101/2020.09.24.312769

Torjesen, 2020, Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear, BMJ, 369, m1555, 10.1136/bmj.m1555

Pyrillou, 2018, Dexamethasone induces omega3-derived immunoresolvents driving resolution of allergic airway inflammation, J Allergy Clin Immunol, 142, 691, 10.1016/j.jaci.2018.04.004

Group, 2020, Dexamethasone in hospitalized patients with Covid-19 - preliminary report, N Engl J Med, 10.1056/NEJMoa2021436

Alessi, 2020, Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes, Diabetol Metab Syndr, 12, 80, 10.1186/s13098-020-00583-7

2020, COVID-19 coagulopathy: an evolving story, Lancet Haematol, 7, e425, 10.1016/S2352-3026(20)30151-4

Klok, 2020, Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thromb Res, 191, 145, 10.1016/j.thromres.2020.04.013

Martin-Rojas, 2020, COVID-19 coagulopathy: An in-depth analysis of the coagulation system, Eur J Haematol, 105, 741, 10.1111/ejh.13501

Pretorius, 2018, Platelet activity and hypercoagulation in type 2 diabetes, Cardiovasc Diabetol, 17, 141, 10.1186/s12933-018-0783-z

Wang, 2018, Hyperglycemia induces neutrophil extracellular traps formation through an NADPH oxidase-dependent pathway in diabetic retinopathy, Front Immunol, 9, 3076, 10.3389/fimmu.2018.03076

Zucoloto, 2019, Platelet-neutrophil interplay: insights into Neutrophil Extracellular Trap (NET)-driven coagulation in infection, Front Cardiovasc Med, 6, 85, 10.3389/fcvm.2019.00085

Abou-Ismail, 2020, The hypercoagulable state in COVID-19: incidence, pathophysiology, and management, Thrombosis Res, 194, 101, 10.1016/j.thromres.2020.06.029

Tang, 2020, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thrombosis Haemostasis, 18, 1094, 10.1111/jth.14817

Rahadian, 2020, Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice, Journal of Atherosclerosis and Thrombosis, 27, 1141, 10.5551/jat.52100

Testa, 2020, Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience, J Thromb Haemost, 18, 1320, 10.1111/jth.14871

Lonnrot, 2017, Respiratory infections are temporally associated with initiation of type 1 diabetes autoimmunity: the TEDDY study, Diabetologia, 60, 1931, 10.1007/s00125-017-4365-5

Yang, 2010, Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes, Acta Diabetol, 47, 193, 10.1007/s00592-009-0109-4

Marchand, 2020, Type 1 diabetes onset triggered by COVID-19, Acta Diabetol, 57, 1265, 10.1007/s00592-020-01570-0

Yang, 2020, A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids, Cell Stem Cell, 27, 125, 10.1016/j.stem.2020.06.015

Carlsson, 1998, Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats, Diabetologia, 41, 127, 10.1007/s001250050880

Sardu, 2020, Hyperglycaemia on admission to hospital and COVID-19, Diabetologia, 63, 2486, 10.1007/s00125-020-05216-2